GGrantIndex
← Search

Comprehensive Cancer Center Program at Fox Chase

$250,000P30FY2021CANIH

Research Inst Of Fox Chase Can Ctr, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

PROJECT SUMMARY Over its eleven-year history, GMaP Region 4 has been highly successful in developing and utilizing effective strategies for enhancing research, training, and outreach/education in the areas of cancer and cancer health disparities and biospecimen research participation. GMaP Region 4 covers the 13 states of Connecticut, Iowa, Illinois, Indiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Rhode Island and Wisconsin. Our Administrative Core, based at Fox Chase Cancer Center (FCCC), is staffed by a strong, dedicated team working in close collaboration with our enduring regional External Advisory Board (EAB) composed of both senior and early stage investigators (ESIs). Our EAB are leaders at their respective institutions, many of whom have benefited from and encourage their colleagues and mentees to seek NCI Continuing Umbrella of Research Experiences (CURE) funding. In addition, the Administrative Core team has been together since the GMaP inception and has had strong senior leadership support from our Cancer Center Director and Cancer Center Leadership team. We have strong institutional support and are integrated with our Community Outreach and Engagement and Academic Affairs departments. Region 4 has shown great achievements in establishing a strong and collaborative membership, a research base for future science, and the ability to make connections that promote scientific growth and professional development. Our membership has grown from 140 members to over 900 investigators from around the region, including many current/former/potential CURE trainees. We typically identify 50+ new members each year and have networked 133 potential CURE scholars to CRCHD over the program history, many of whom have gone on to successful awards. We have provided 123 travel awards and 7 mentored grant application reviews (4 awarded, 2 pending, 1 resubmitted and pending). Our pilot program has resulted in three 2017 pilot grants which have fostered 17 publications, 12 oral and 2 poster presentations, and 9 applications for funding (1 awarded, 6 not awarded, 2 pending). In response to the COVID 19 pandemic, we funded four pilot grants in March 2020 slated to be completed by June 2021 in place of travel awards and in-person networking. This combination of strong leadership, dedicated diverse membership, and career-building programs to support underrepresented investigators has been a winning combination. Over the next 2 years, we will continue to meet our goals through our existing programs, expand and strengthen our diverse network, develop and conduct a mixed-methods evaluation with our members and scholars, work with CRCHD and the Diversity Training Branch (DTB) to transition our scholars and network to a sustainable model connected to CRCHD and DTB, and measure the impact of these efforts.

View original record on NIH RePORTER →
Comprehensive Cancer Center Program at Fox Chase · GrantIndex